Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q4 FY2024 (2024-12-31): -383.35%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-231.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NeuroSense Therapeutics Ltd.
Market Cap
$6.95M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
-231.20%
5Y Avg
N/A
Market Cap
$6.97M
Return on Invested Capital (ROIC)
-219.15%
TTM Avg
-109.13%
3Y Avg
-72.14%
5Y Avg
-33.59%
Market Cap
$7.00M
Return on Invested Capital (ROIC)
-232.05%
TTM Avg
-321.25%
3Y Avg
-211.94%
5Y Avg
-167.22%
Market Cap
$6.87M
Return on Invested Capital (ROIC)
-90.17%
TTM Avg
-79.44%
3Y Avg
-64.42%
5Y Avg
-71.54%
Market Cap
$7.07M
Return on Invested Capital (ROIC)
-208.39%
TTM Avg
-54.78%
3Y Avg
-47.23%
5Y Avg
-47.23%
Market Cap
$6.82M
Return on Invested Capital (ROIC)
-101.07%
TTM Avg
-100.00%
3Y Avg
-93.40%
5Y Avg
-94.83%
Market Cap
$6.72M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-251.59%
3Y Avg
-2172.61%
5Y Avg
-1769.42%
Market Cap
$7.18M
Return on Invested Capital (ROIC)
-211.58%
TTM Avg
-206.45%
3Y Avg
-187.44%
5Y Avg
-143.49%
Market Cap
$6.60M
Return on Invested Capital (ROIC)
-57.11%
TTM Avg
-311.64%
3Y Avg
-524.77%
5Y Avg
-524.77%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $6.95M | N/A | N/A | -231.20% | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.97M | -219.15% | -109.13% | -72.14% | -33.59% |
| KALA BIO, Inc. (KALA)vs › | $7.00M | -232.05% | -321.25% | -211.94% | -167.22% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.87M | -90.17% | -79.44% | -64.42% | -71.54% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | -208.39% | -54.78% | -47.23% | -47.23% |
| Exicure, Inc. (XCUR)vs › | $6.82M | -101.07% | -100.00% | -93.40% | -94.83% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.72M | N/A | -251.59% | -2172.61% | -1769.42% |
| Longeveron Inc. (LGVN)vs › | $7.18M | -211.58% | -206.45% | -187.44% | -143.49% |
| Aclarion, Inc. (ACON)vs › | $6.60M | -57.11% | -311.64% | -524.77% | -524.77% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.65M | -107.99% | -407.39% | -445.97% | -342.27% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2024-12-31 | -383.35% |
| 2023-09-30 | -494.53% |
| 2023-06-30 | -270.74% |
| 2023-03-31 | -374.90% |
| 2022-12-31 | -226.47% |
| 2022-09-30 | -140.37% |
| 2022-06-30 | -87.52% |
| 2022-03-31 | -51.34% |
| 2021-12-31 | -51.57% |
| 2021-06-30 | -565.64% |
| 2021-03-31 | -709.26% |
| 2020-12-31 | -438.24% |
